PHARMACEUTICAL 2026

Madrigal Pharmaceuticals INC
Rank 87 of 178



PHARMACEUTICAL 2026

Madrigal Pharmaceuticals INC
Rank 87 of 178

The relative strengths and weaknesses of Madrigal Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Madrigal Pharmaceuticals INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 49% points.The greatest weakness of Madrigal Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is 236%, being 6.4% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	1,245,770
Cost of Goods Sold	0
Intangible Assets	7,381
Liabilities, Current	310,288
Liabilities, Non-Current	346,612
Other Assets	4,939
Other Compr. Net Income	405
Other Expenses	78,457
Other Liabilities	0
Other Net Income	34,122
Other Revenues	958,403
Property and Equipment	1,499
Research and Development	388,525
Selling, General and Administrative Expense	813,827

Output Variable	Value in 1000 USD
Assets	1,259,589
Liabilities	656,900
Expenses	1,280,809
Revenues	958,403
Stockholders Equity	602,689
Net Income	-288,284
Comprehensive Net Income	-288,082
BaseVar	2,095,114
ECR before LimitedLiability	107%
Economic Capital Ratio	236%